• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Biomarker Partnering Yearbook 2013 Product Image

Biomarker Partnering Yearbook 2013

  • Published: January 2013
  • Region: Global
  • 200 pages
  • CurrentPartnering

The Biomarker Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.

Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2012’s dealmaking and business activities.

Chapter 1 provides an overview of the trends in dealmaking during 2012 covering trends by deal type, stage of development, technology type and therapeutic indication.

Chapter 2 provides a review of the leading deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents READ MORE >

Executive Summary

Chapter 1 – Trends in dealmaking during 2012

1.1. Bigpharma dealmaking activity

1.2. Partnering by deal type

1.3. Partnering by industry sector

1.4. Partnering by stage of development

1.5. Partnering by technology type

1.6. Partnering by therapy area

Chapter 2 – Leading deals during 2012

2.1. Introduction

2.2. Top deals by value during 2012

Chapter 3 – Bigpharma deals during 2012

3.1. Introduction

3.2. How to use bigpharma partnering deals

3.3. Bigpharma partnering company profiles for 2012

Abbott

Actavis

Actelion

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Galderma

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Otsuka

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Shire

Takeda

Teva

Valeant

Warner Chilcott

Watson

Chapter 4 – Partnering deals directory 2012

4.1. Introduction

4.2. Company A-Z

4.3. By deal type

4.4. By stage of development

4.5. By technology type

4.6. By therapy area

About Wildwood Ventures

Current Partnering

Current Agreements

Current Reports

Recent titles from CurrentPartnering

Order Form – Reports

Table of figures

Figure 1: Bigpharma – top 50 – January to December 2012

Figure 2: Bigpharma deal frequency – 2012

Figure 3: Partnering by deal type during 2012

Figure 4: Partnering by industry sector during 2012

Figure 5: Partnering by stage of development during 2012

Figure 6: Partnering by technology type during 2012

Figure 7: Partnering by therapy area during 2012

Figure 8: Top deals by value during 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos